Reading GNLX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GNLX free→Reading GNLX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GNLX free→QuarterlyIQ Insights · GNLX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. On March 19, 2026, Genelux Corporation (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”), pursuant to which the Company may, from time to time, offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Placement Shares”), having an aggregate offering price of up to $100,000,000, through TD Cowen, acting as the Company’s sales agent and/or principal. The Placem…
Other Events. Underwritten Public Offering On January 8, 2026, Genelux Corporation (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Lucid Capital Markets, LLC ( the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten offering (the “Offering”) an aggregate of 6,666,667 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a price to the public of $3.00 per share. A…
Other Events. On January 5, 2026, Genelux reported interim results from two ongoing trials evaluating systemic (intravenous) administration of Olvi-Vec in patients with progressive small cell lung cancer and progressive non-small cell lung cancer, respectively, after failure of prior platinum-based regimens. Platinum-relapsed or platinum-refractory advanced SCLC (Phase 1b/2 SCLC trial) The open-label Phase 1b/2 SCLC trial ( NCT07136285 ) is evaluating a single intravenous cycle with multiple…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Principal Officer or Named Executive Officer On December 30, 2025, Paul Scigalla, M.D. resigned as Chief Medical Officer of Genelux Corporation (the “ Company ”), effective immediately. Appointment of Jason Litten, M.D. as Chief Medical Officer On January 2, 2026, the Company announced the appointment of Jason Litten, M.D. as the Compa…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 1, 2025 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of Genelux Corporation (the “ Company ”) approved a reduction in the exercise prices of certain outstanding options to purchase shares of the Company’s common stock (the “ Common Stock ”) under the Company’s 2022 Equity Incentive Plan (the “ 2022 Plan ”), 2019 Equ…
Other Events. On March 25, 2025, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group, a division of American Capital Partners (the “Underwriter”), pursuant to which the Company agreed to issue and sell in an underwritten registered direct offering (the “Offering”) an aggregate of 3,000,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a public offering price of $3.50 per share. T…
Results of Operations and Financial Condition. Genelux Corporation (the “Company”) estimates that its cash, cash equivalents and short-term investments as of December 31, 2024 were approximately $30.9 million. The Company has not yet completed its quarter-end or year-end financial close process for the quarter and year ended December 31, 2024. This estimate of the Company’s cash, cash equivalents and short-term investments as of December 31, 2024 is preliminary, has not been audited and is su…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.